Galmed Pharmaceuticals Ltd.

DB:GPH Stock Report

Market Cap: €3.9m

Galmed Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Allen Baharaff

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage40.6%
CEO tenure24.8yrs
CEO ownershipn/a
Management average tenure7.7yrs
Board average tenure8.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Allen Baharaff's remuneration changed compared to Galmed Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$6m

Jun 30 2024n/an/a

-US$6m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$1mUS$551k

-US$7m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$605k

-US$18m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$3mUS$632k

-US$32m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$503k

-US$29m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$1mUS$486k

-US$20m

Sep 30 2019n/an/a

-US$16m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018US$2mUS$384k

-US$10m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$12m

Mar 31 2018n/an/a

-US$12m

Dec 31 2017US$1mUS$384k

-US$12m

Compensation vs Market: Allen's total compensation ($USD1.36M) is above average for companies of similar size in the German market ($USD471.55K).

Compensation vs Earnings: Allen's compensation has been consistent with company performance over the past year.

CEO

Allen Baharaff (59 yo)

24.8yrs

Tenure

US$1,356,184

Compensation

Mr. Allen Baharaff has been the Chief Executive Officer of Galmed Pharmaceuticals Ltd. since January 2012 and has been its President since March 2015. Mr. Baharaff co-founded the Galmed Pharmaceuticals Ltd...

Leadership Team

NamePositionTenureCompensationOwnership
Allen Baharaff
Co-Founder24.8yrsUS$1.36mno data
Doron Cohen
Chief Financial Officer2.8yrsUS$273.81k0.0011%
€ 44.6
Guy Nehemya
COO & Data Protection Officer7.7yrsUS$374.78k0.0021%
€ 81.3
Yohai Stenzler
Chief Accounting Officer2.8yrsUS$378.32k0.0021%
€ 81.3
Liat Hayardeny
Chief Scientific Officer8.2yrsUS$114.69k0%
€ 0
Tali Gorfine
Medical Consultant7.7yrsUS$382.51kno data

7.7yrs

Average Tenure

55.5yo

Average Age

Experienced Management: GPH's management team is seasoned and experienced (7.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Allen Baharaff
Co-Founderno dataUS$1.36mno data
David Sidransky
Lead Independent Director10.4yrsno data0.0028%
€ 110.2
Carol Brosgart
Independent Director7.4yrsno data0%
€ 0
José Mato de la Paz
Member of Scientific Advisory Boardno datano datano data
Scott L. Friedman
Member of Scientific Advisory Boardno datano datano data
Arun Sanyal
Member of Scientific Advisory Boardno datano datano data
Vlad Ratziu
Member of Scientific Advisory Boardno datano datano data
Shmuel Nir
Independent Director17.8yrsno data0.0028%
€ 110.2
Amir Poshinski
Independent Director4.4yrsno data0%
€ 0
Shomron Ben-Horin
Member of Scientific Advisory Boardno datano datano data

8.9yrs

Average Tenure

63yo

Average Age

Experienced Board: GPH's board of directors are considered experienced (8.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/11/25 21:36
End of Day Share Price 2024/08/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Galmed Pharmaceuticals Ltd. is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Edward NashCanaccord Genuity
Elemer PirosCantor Fitzgerald & Co.